Physician profile
Kendall Mault
NPI 1851607014
$3,343.81
in general payments reported to CMS, 2019-2025
19 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $165 · 2021: $280 · 2022: $326 · 2023: $365 · 2024: $699 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $707.37 | 2019-2025 | Cequa |
| Abbvie INC. | $644.89 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $359.37 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $261.02 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $213.63 | 2022-2025 | Hydrus Microstent, Voyager Dslt, Rocklatan |
| Novartis Pharmaceuticals Corporation | $193.64 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $188.43 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $167.49 | 2019-2025 | |
| Oyster Point Pharma, INC. | $143.69 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $113.73 | 2020-2021 | |
| Dompe US, INC. | $110.99 | 2020-2023 | Oxervate |
| Amgen INC. | $73.07 | 2024-2025 | Tepezza |
| Shire North American Group INC | $39.27 | 2019 | |
| Kala Pharmaceuticals, INC. | $38.34 | 2020-2021 | |
| Allergan, INC. | $29.45 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $20.57 | 2025 | Iyuzeh |
| Eyepoint US, INC. | $19.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.90 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Mault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.